Lipidor AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.lipidor.se
Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Phase 1
1 (33.3%)Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: AKVANO-Calcipotriol formulation 1Drug: AKVANO-Calcipotriol formulation 2Drug: AKVANO vehicle formulation 1Drug: AKVANO vehicle formulation 2Drug: Daivonex solutionDrug: Daivonex cream
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Lipidor AB
- Target Recruit Count
- 24
- Registration Number
- NCT05488990
- Locations
- 🇩🇪
bioskin GmbH, Bergmannstrasse 5, Berlin, Germany
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
Phase 3
- Conditions
- Mild to Moderate Psoriasis
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Lipidor AB
- Target Recruit Count
- 294
- Registration Number
- NCT05249972
- Locations
- 🇮🇳
Lotus Multispeciality Hospital, Ahmedabad, India
News
Lipidor's Phase III Psoriasis Trial Reaches Halfway Enrollment Mark, Results Expected in April
Lipidor AB has announced that half of the patients have been randomized in its Phase III clinical study of AKP02G2 for mild to moderate psoriasis.
Lipidor AB Initiates Phase III Trial of AKP02G2 for Psoriasis Treatment
Lipidor AB has enrolled the first patient in its Phase III clinical trial evaluating AKP02G2, a topical spray for mild to moderate psoriasis.